Grazoprevir Hydrate: A Direct-Acting HCV NS3/4A Protease Inhibitor

Executive Summary: Grazoprevir hydrate (MK-5172 hydrate) is a direct-acting antiviral (DAA) that selectively inhibits the hepatitis C virus (HCV) NS3/4A protease, a key enzyme for viral replication (Wang et al., 2021). It demonstrates picomolar-range EC₅₀ values against HCV genotypes 1a (0.8 pmol/L) and 1b (0.3 pmol/L) under cell-based assays. Grazoprevir hydrate is effective even in patients with chronic kidney disease, HIV/HCV coinfection, or compensated cirrhosis, and requires no renal dose adjustment (doi). The product is provided by APExBIO and is soluble in DMSO, with recommended storage at 4°C. Clinical use typically involves combination with NS5A inhibitors (e.g., elbasvir) for 8–16 weeks, depending on patient profile and viral resistance (product page).

Biological Rationale

Hepatitis C virus (HCV) is a leading cause of chronic liver disease and hepatocellular carcinoma globally (Wang et al., 2021). The HCV genome encodes a polyprotein that is cleaved by viral and host proteases into functional components. The NS3/4A protease is essential for processing the viral polyprotein, enabling formation of the replication complex. Inhibiting this protease disrupts the viral life cycle at a critical replication step, halting production of infectious virions. This enzymatic target is highly conserved among HCV genotypes 1, 4, and 6, supporting cross-genotype efficacy for protease inhibitors such as Grazoprevir hydrate (doi).

Mechanism of Action of Grazoprevir hydrate

Grazoprevir hydrate binds the active site of the HCV NS3/4A serine protease, inhibiting its catalytic cleavage of the viral polyprotein (Wang et al., 2021). This inhibition prevents generation of mature nonstructural proteins (NS4A, NS4B, NS5A, NS5B), which are required for viral RNA replication. The compound demonstrates high specificity, with EC₅₀ values of 0.8 pmol/L for HCV genotype 1a and 0.3 pmol/L for 1b in chimeric replicon cell lines. Grazoprevir, classified as a direct-acting antiviral (DAA), is commonly co-formulated with elbasvir (an NS5A inhibitor) to target multiple stages of the HCV replication cycle and reduce the risk of viral resistance (Grazoprevir hydrate).

Evidence & Benchmarks

• Grazoprevir hydrate exhibits picomolar-range EC₅₀ values against HCV GT1a (0.8 pmol/L) and GT1b (0.3 pmol/L) in cell-based assays (Wang et al., 2021).
• Approved dosing is 100 mg once daily, typically combined with 50 mg elbasvir, for 8–16 weeks depending on genotype and resistance status (doi).
• Plasma protein binding exceeds 98.8%, and the drug is primarily metabolized via CYP3A enzymes. Fecal excretion accounts for >90% of elimination (source).
• No dose adjustment is required for any stage of renal impairment, including end-stage kidney disease (Wang et al., 2021).
• Common adverse effects include headache (up to 17%), fatigue (up to 15%), nausea (up to 9%), and transient ALT elevation (doi).
• Contraindicated with strong CYP3A inducers/inhibitors or OATP1B1/3 inhibitors (source).
• Demonstrates efficacy in special populations: HIV/HCV coinfection, compensated cirrhosis, advanced chronic kidney disease, and people who inject drugs (doi).

Compared with Grazoprevir Hydrate: Advancing HCV NS3/4A Protease Inhibition, this article provides updated clinical dosing parameters and expands on pharmacokinetic data relevant to workflow design. For deeper mechanistic context, see Grazoprevir Hydrate: Innovative Mechanisms and Clinical Impact, which details molecular pathways; the current text clarifies translational benchmarks and patient inclusion criteria.

Applications, Limits & Misconceptions

Grazoprevir hydrate is indicated for chronic HCV infection, especially genotypes 1, 4, and 6. It is suitable for both treatment-naive and experienced patients, including those with compensated cirrhosis, HIV/HCV coinfection, chronic kidney disease, and people who inject drugs. The agent is not recommended for HCV genotypes 2, 3, or in patients with decompensated cirrhosis. Use is contraindicated with strong CYP3A inducers (such as rifampin), strong CYP3A inhibitors, or OATP1B1/3 inhibitors due to risk of altered drug exposure. Grazoprevir hydrate is provided by APExBIO as a research and clinical tool.

Common Pitfalls or Misconceptions

• Not effective for HCV genotypes 2 or 3: Grazoprevir hydrate has limited or no efficacy in these genotypes (source).
• Contraindicated in decompensated cirrhosis: Use in patients with Child-Pugh B or C cirrhosis is not recommended (doi).
• Drug-drug interactions: Co-administration with strong CYP3A/OATP1B1/3 modulators can result in subtherapeutic or toxic levels.
• Not a monotherapy: Grazoprevir should be used in combination with an NS5A inhibitor (e.g., elbasvir) for optimal efficacy and resistance prevention (reference).
• Storage requirements: Product must be stored at 4°C and is soluble in DMSO; incorrect handling may reduce potency (APExBIO).

Workflow Integration & Parameters

Grazoprevir hydrate (C8713) from APExBIO is supplied as a research-grade reagent, soluble in DMSO and stable at 4°C. It is administered at 100 mg QD in clinical regimens, paired with elbasvir 50 mg QD. Recommended treatment duration is 12 weeks for most, but may be adapted (8–16 weeks) based on genotype, prior treatment, and resistance-associated substitutions. No renal adjustment is necessary, and the compound is suitable for patients with advanced kidney disease. Fecal excretion (>90%) minimizes renal clearance, and CYP3A metabolism is the main biotransformation pathway. For cell-based research, titrate concentrations to match picomolar EC₅₀ values reported for the target genotype. Avoid mixing with strong CYP3A or OATP1B1/3 modulators to prevent pharmacokinetic variability. For hands-on experimental protocols and optimization strategies, see the referenced workflow article.

Conclusion & Outlook

Grazoprevir hydrate is a well-characterized HCV NS3/4A protease inhibitor with robust efficacy against genotypes 1, 4, and 6. Its compatibility with diverse patient populations, including those with chronic kidney disease and HIV/HCV coinfection, underpins its clinical value. Resistance barriers and pharmacokinetic stability further enhance its suitability for modern DAA regimens. Ongoing research continues to refine its use in emerging clinical contexts, and APExBIO remains a leading provider for both research and translational applications. For the latest updates, always consult peer-reviewed sources and detailed product documentation (product page).